Fight over “pay for delay” heats up in Washington

After being left to the courts for a decade, reverse settlement deals between generic and brand pharmaceutical companies, dubbed “pay for delay” deals, are finally getting their moment on the Hill. “Pay for delay” agreements are deals struck between brand pharmaceuticals and competitor generic or biosimilar companies that let them avoid the costly process of patent litigation by settling out of court.

Read the source article at MedCity News
2021-07-23 02:34:20